Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
December 01, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
Celyad Announces Third Quarter 2015 Business Update
November 19, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
November 10, 2015 01:00 ET
|
Celyad
No treatment-related safety issues reported at 30 days post-treatment of all patients in first cohort of the trial following single dose NKG2D CAR T-Cell infusion
Triggers enrolment of first...
Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts
November 06, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified to Reduce Immunogenicity is Awarded to Celyad
October 23, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Oct. 23, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
Celyad Announces the Appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology
September 15, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director
September 04, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China
August 31, 2015 01:00 ET
|
Celyad
All costs leading to market approval to be paid by local partner
New agreement contains high double digit royalties and profit sharing
MONT-SAINT-GUIBERT, Belgium, Aug. 31, 2015 (GLOBE NEWSWIRE)...
Celyad Reports First Half 2015 Financial Results and Operational Progress
August 25, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development...
Celyad Announces Details of Upcoming Half Year 2015 Financial Results
August 12, 2015 01:30 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development...